We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- The need to characterize vaccine-indued immunity in more detail
- Methods for comparison of convalescent versus vaccination-induced plasma
- Higher effectiveness of antibodies induced by mRNA vaccination
- Characteristics of the new lambda variant – implications for immune escape
- Mechanisms leading to the increased efficiency of vaccine-induced antibodies compared to those of recovered patients.
Biography
Dr Nathaniel “Ned” Landau is a professor in the NYU Grossman School of Medicine in the Department of Microbiology. Ned Submitted his doctoral thesis studies at MIT, followed by post-doctoral studies at the University of California, San Francisco. He then became an independent investigator at the Aaron Diamond AIDS Research Center in New York and subsequently at The Salk Institute in La Jolla, California. His research has been in Immunology and Virology with a focus on the cellular receptors that mediate HIV entry and the role of the lentiviral accessory proteins in virus replication. His research has now expanded to studies on the adaptive and innate immune response to SARS-CoV-2.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Landau, N. (2021, October 18). Comparison of immune resilience induced by vaccination versus COVID recovery [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 1, 2023, from https://hstalks.com/bs/4797/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Ned Landau has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Comparison of immune resilience induced by vaccination versus COVID recovery
Published on October 18, 2021
14 min
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Nathaniel Landau (or Ned Landau),
thank you very much for taking the time to do this interview with us today, to update us on
the potential for novel SARS-CoV-2 variants to evade vaccine-induced immunity,
resulting in the development of Covid in mRNA-vaccinated individuals.
First of all, what was the initial aim of the investigation you conducted,
where the neutralizing efficiency of convalescent sera (i.e. those taken from recovered patients)
was compared to that of individuals vaccinated against SARS-CoV-2, with mRNA vaccines in particular?
Prof. Landau: The original vaccines, as they were formulated, were against the earlier forms of SARS-CoV-2,
so they raise antibodies that are specific to that particular spike protein,
but more recently, the virus has mutated and the spike protein is a little bit different.
The question was to determine how well antibodies that were raised by the vaccine
- as well as antibodies raised by somebody who was naturally infected with the earlier form of the virus -
how well those antibodies would neutralize the newer forms of the virus.
This would give us an idea of how well the vaccines will retain their ability to protect against
infection with the more recent forms of the virus, as well as how well somebody who was infected
with the earlier virus will be protected from becoming reinfected.
Hide